The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

The investment, which the foundation says is its largest in women’s health to date, will support research in maternal health, ...

Positive results from a mid-stage study apparently weren’t enough to raise investor confidence in Praxis Precision Medicines ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...